Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20020 (
adenosine triphosphatase
)
3,299
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Exposing micro-dissected pancreatic islets of non-inbred ob/ob mice to 2-5 mM-
alloxan
for 10 min decreased the ability of the islets to accumulate Rb+. Rb+ accumulation in pieces of exocrine pancreas was unaffected by
alloxan
. When islets were treated with
alloxan
in the presence of 2-20 mM-D-glucose, the Rb+-accumulating ability was protected in a dose-dependent manner. The protective action of D-glucose was reproduced with 3-O-methyl-D-glucose but not with L-glucose or D-mannoheptulose; mannoheptulose prevented D-glucose from exerting its protective action. The inhibition of Rb+ accumulation was due to a decreased inward pumping, since
alloxan
did not affect Rb+ efflux from pre-loaded islets. The inhibitory effect of
alloxan
had a latency of about 1 min, as revealed by experiments with dispersed islet cells in suspension.
Alloxan
-treated islets showed only a marginal decrease in ATP and no change in glucose 6-phosphate concentration. Although
alloxan
slightly decreased the hydrolysis of ATP in a subcellular fraction enriched in plasma membranes, this effect could not be attributed to a ouabain-sensitive
adenosine triphosphatase
. The plasma membranes exhibited a K+-activated hydrolysis of p-nitrophenyl phosphate; this enzyme activity too was insensitive to
alloxan
. Glucose may protect the univalent-cation pump by preventing permeation of
alloxan
via a path coupled to the hexose-transport system. Inhibition of the pump may be fundamental to the induction of
alloxan
-diabetes.
...
PMID:Alloxan cytotoxicity in vitro. Inhibition of rubidium ion pumping in pancreatic beta-cells. 19 15
Changes in the cation balance cause hydration and initiate the process of lens opacification. Such alterations were studied in human cataractous lenses and during the development of
alloxan
-induced diabetic cataract in rats by biochemical and histochemical techniques. The development of
alloxan
-induced cataract in rats was examined in vivo which showed cortical opacities beginning after 32 days. These opacities did progress to maturity after 64 days and finally the lenses were completely opacified after 96 days of
alloxan
treatment. The histochemical localization of sodium-potassium-activated
adenosine triphosphatase
using three different methods provided information on the possible role of this enzyme in normal and cataractous lenses. In human cataractous lenses, sodium-potassium
adenosine triphosphatase
activity was found to be considerably decreased, whereas no activity of this enzyme was localized in human diabetic cataractous lenses. An animal model provided evidence that an apparent decrease of sodium-potassium
adenosine triphosphatase
may be involved in the initiation of
alloxan
-induced diabetic cataract in rats.
...
PMID:Studies on cataractogenesis in humans and in rats with alloxan-induced diabetes. I. Cation transport and sodium-potassium-dependent ATPase. 298 22